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Abstract 
Background: After implementation of the PREDICA annual chest X-ray (CXR) screening program in smokers in the 
general practice setting of Varese-Italy a significant reduction in lung cancer-specific mortality (18 %) was observed. 
The objective of this study covering July 1997 through December 2006 was to estimate the cost-effectiveness of this 
intervention.
Methods: We examined detailed information on lung cancer (LC) cases that occurred among smokers invited to 
be screened in the PREDICA study (Invitation-to-screening Group, n = 5815 subjects) to estimate costs and quality-
adjusted life-years (QALYs) from LC diagnosis until death. The control group consisted of 156 screening-eligible smok-
ers from the same area, uninvited and unscreened, who developed LC and were treated by usual care. We calculated 
the incremental net monetary benefit (INMB) by comparing LC management in screening participants (n = 1244 
subjects) and in the Invitation-to-screening group versus control group.
Results: The average number of QALYs since LC diagnosis was 1.7, 1.49 and 1.07, respectively, in screening partici-
pants, the invitation-to-screening group, and the control group. The average total cost (screening + management) 
per LC case was higher in screening participants (€17,516) and the Invitation-to-screening Group (€16,167) than in the 
control group (€15,503). Assuming a maximum willingness to pay of €30,000/QALY, we found that the intervention 
was cost-effective with high probability: 79 % for screening participation (screening participants vs. control group) and 
95 % for invitation-to-screening (invitation-to-screening group vs. control group).
Conclusions: Based on the PREDICA study, annual CXR screening of high-risk smokers in a general practice setting 
has high probability of being cost-effective with a maximum willingness to pay of €30,000/QALY.
Keywords: Lung cancer, Chest X-ray screening, Cost-effectiveness, Cost-utility
© 2015 Pertile et al. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
Lung cancer (LC) is the most deadly malignancy, with 
an estimated 1,200,000 deaths each year worldwide [1]. 
More than 85 % of LC deaths are attributable to smoking 
cigarettes; therefore, tobacco control and smoking cessa-
tion are the interventions most commonly used to reduce 
LC morbidity and mortality [1, 2]. Because heavy smokers 
remain at high risk for many years, even after quitting 
[3], screening for LC is another intervention to consider. 
Screening aims to diagnose the disease at an early stage, 
when it is potentially curable with appropriate treat-
ment protocols [4–7]. After lengthy methodological con-
troversy over the efficacy of screening for LC, in recent 
years the results of observational screening with chest 
computed tomography (CT) in heavy smokers has shown 
a significant reduction of LC mortality [8]; with chest 
X-ray (CXR) screening the LC mortality reduction was 
less pronounced but still significant [9, 10]. After publica-
tion in 2011 of the National Lung Screening Trial (NLST) 
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results, which showed a 20 % reduction in LC mortality 
with CT screening compared with CXR screening [11], 
major cancer organizations began to advocate for low-
dose chest CT screening with the NLST criteria [12]. 
However, depending on the model and the assumptions 
applied, estimates of the cost-effectiveness of CT screen-
ing ranged widely, from $19,500 (USD) [13] to $2,322,700 
[14] per quality-adjusted life-year (QALY) gained. The 
wide divergence of these estimates contributes to the 
current uncertainty about cost-effectiveness and afford-
ability of CT screening in the general population setting 
[15–18]. While CT screening has been extensively ana-
lyzed, including its economic implications, the assess-
ment of cost-effectiveness of CXR screening in smokers 
has received little attention. CXR as a LC screening tool 
is definitely less sensitive than chest CT [19], however it 
is more specific [20] and there are several clinical reasons 
why the cost-effectiveness of screening with chest radio-
graph may be worth investigating. With CXR screening 
there is not only a lower probability of false positive tests, 
but also less LC overdiagnosis and lower radiation doses 
than with CT screening [21, 22]. Moreover, from an eco-
nomic perspective CXR is a relatively inexpensive and 
broadly accessible exam, two highly favorable features in 
a screening tool. Despite this, we are only aware of one 
cost-effectiveness analysis of CXR screening, based on 
the model developed by Caro et al. [23], where the esti-
mated cost per discounted life-years gained ranged from 
$19,874 (USD) to $59,621 (USD). Before that, Strauss 
[24] made only a “crude analysis” (p. 768), leading to an 
estimate of $7900 per life-year saved. It was previously 
reported that a population-based CXR screening pro-
gram which targeted smokers (PREDICA) decreased LC 
mortality by 18 % [9], and we made an initial estimate of 
the total incremental cost of screening [25]. In this paper 
we use the data from the PREDICA cohort [26] to inves-
tigate the cost-utility of CXR screening for LC. Our aim 
is to evaluate the cost-utility of the screening program in 
the total invitation-to-screen PREDICA cohort, includ-
ing self-selected participants as well as individuals who 
were invited to the screening but decided not to partici-
pate. With this “intention-to-screen approach”, the analy-
sis of cost-effectiveness overcomes the well-known bias 
of participants’ self-selection [27] and allows estimates 
of the screening program’s overall impact on the target 
population.
Methods
Overview of the PREDICA study
In 1997 we began a prospective observational study, the 
PREDICA study (ISRCTN90639073), in a clearly defined 
population-based cohort of smokers. The cohort con-
sisted of all smokers of >10 pack-years, aged 45–75 years, 
resident in 50 communities of the Province of Varese-
Italy, who were screening-eligible (n  =  5815 subjects). 
These subjects were invited by their National Health Ser-
vice (NHS) general practitioner to receive an annual LC 
screening with CXR for 4  years, according to an estab-
lished protocol [26]. The PREDICA cohort was observed 
from July 1, 1997 until the end of the study (December 
31, 2010), a total of 13.5 years. The cohort’s demographic 
characteristics, adherence to screening, LC detection 
results, LC survival rate, and LC mortality have been 
published [9, 26]. Because some information relevant to 
the economic analysis was missing after 2006, the obser-
vational interval used in this study ends with December 
31, 2006. For the period until the end of 2006, clinical 
data were gathered, which allow to assign each patient 
to one of the LC stages associated with a specific value 
of the Quality of Life, presented later under “Utilities”. 
Moreover, the main events related to substantial resource 
use were also recorded, including surgery, radiotherapy, 
chemotherapy, follow-up exams.
Defining the invitation‑to‑screening group and screening 
participants
In the present study of cost-effectiveness of CXR screen-
ing, the PREDICA cohort of 5,815 subjects is referred 
to as the Invitation-to-screening Group. Of the sub-
jects invited to the screening program, 1244 (21  %) 
agreed to participate and are referred to as the Screening 
Participants.
Defining lung cancer patient/lung cancer death
In the Invitation-to-screening Group we defined LC 
patients as those who presented with a new clinical or 
pathological diagnosis of LC—after excluding screen-
ing-ineligible candidates (i.e., subjects unfit for surgery 
or with diagnosed or suspected LC as of July 1997). 
Through linkage with the Varese Mortality Registry and 
the Lombardy Health Registry of residents we identified 
LC deaths (codes 162.2–162.9 of the International Clas-
sification of Diseases, Edition IX) that occurred in the 
Invitation-to-screening Group during the study period. 
Information on date and cause of death were obtained 
from the Registry death certificates. Cause of death was 
definitively attributed to LC after review by the mortal-
ity review committee, as previously described [26]. The 
characteristics of the LC cases reported for the Screening 
Participants, the Invitation-to-screening Group, and the 
Control Group are summarized in Table 1.
Timeline of economic evaluation of screening 
and follow‑up of lung cancer cases
For the purposes of the economic analysis, the LC cases 
were followed until death or December 31, 2006. For 
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patients alive at the end of the observational period, we 
have censored observations. The different proportions 
of these cases in the different groups (see Table 1)—due 
partly to the different recruitment periods—implies 
a potential bias in the analysis from underestimation 
of both costs and QALYs for these patients. The way in 
which we addressed this potential source of bias is dis-
cussed below under “Utilities” and “Costs”.
Control group
A Control Group consisting of uninvited and unscreened 
LC patients, prospectively followed-up long term, was 
identified and used as comparator for LC cases found in 
the Invitation-to-screening Group. We accessed the data-
base of all LC cases (n =  243) diagnosed during calen-
dar year 2000 among the 350,000 residents of the Varese 
district. The year 2000 LC cases were chosen because (1) 
they were nearly contemporary with the LC cases of the 
Invitation-to-screening Group, (2) they came from the 
same geographical area, and (3) their demographic and 
clinico-pathological data were available and published 
[28]. Of the 243 LC patients diagnosed in 2000, 156 sub-
jects met the screening criteria as of July 1997 (birth-year 
cohort, smoking history, residence in the district of the 
cohort, uninvited to screening and unscreened) and con-
stituted the Control Group. Follow-up of these 156 LC 
cases was obtained through linkage with the Varese Epi-
demiology Observatory [29].
Management of lung cancer patients
The LC cases diagnosed in the Invitation-to-screening 
Group—regardless of the detection modality by screen-
ing or outside screening—and the LC cases diagnosed in 
the Control Group both received NHS’s usual care and 
treatment, with management centralized in the Varese 
University Hospital. The diagnostic procedures for fol-
low-up and diagnosis of individuals with suspect LC have 
been described previously [26]. For patients who refused 
biopsy or treatment and for candidates for supportive 
care only, the LC diagnosis was clinico-radiologic. Treat-
ment of ascertained LC cases—surgery, chemotherapy 
(induction and/or adjuvant), radiotherapy, palliation—
was effected following international criteria [28], based 
on histologic subtype (non-small cell lung cancer, small 
cell lung cancer) and stage (6th ed. of TNM Classification 
of Malignant Tumors) [30].
Economic evaluation
We assessed LC screening program cost-utility using the 
public health system perspective: utility was measured 
through QALYs. We estimated the incremental cost-util-
ity of LC screening through two comparisons. The obvi-
ous comparison was between screening participants and 
the control group; the other comparison was between 
the Invitation-to-screening group and the control group. 
The rationale for the latter comparison was to avert the 
self-selection bias of participants [27] and to explore the 
Table 1 Characteristics of  lung cancer (LC) cases diagnosed between  July 1, 1997 and  December 31, 2006 in  screening 
participants, invitation-to-screening group and control group [26]
IQR interquartile range, CI confidence interval
* Expressed as months from LC diagnosis until death, or until the end of observational period (December 31, 2006)
a Not available in 1 screening participant
b Not available in 5 subjects of invitation-to-screening group
Variable Screening participants  
(67 LC cases)
Invitation‑to‑screening  
group (245 LC cases)
Control group 
(156 LC cases)
Age, median (IQR) 66 (60–72) 68 (60–73) 68 (62–73)
Gender M/F 60/7 221/24 144/12
Smoking habit, n (%)a,b
 Ex smokers 16 (24) 60 (25) 77 (49)
 Smokers 50 (76) 180 (75) 79 (51)
LC stage at diagnosis, n (%)
 I 21 (32) 49 (21) 23 (15)
 II 3 (5) 13 (6) 9 (6)
 III/IV 41 (63) 166 (73) 122 (79)
 Indeterminate/not available 2 17 2
 LC cases with censored follow-up*, n (%) 21 (31 %) 57 (23 %) 12 (8 %)
 LC follow-up months*, median (IQR) 14.03 (30.82) 11.89 (22.54) 8.20 (15.82)
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overall impact of invitation to screening (greater atten-
tion to early symptoms of LC among all invitees and 
among the general practitioners who accepted to recruit 
smokers for the PREDICA study).
Utilities
To assign utilities, for each patient we considered the 
duration of the following phases of LC clinical course: 
diagnosis, chemotherapy, post-operative, free of disease, 
progression, terminal phase. For each phase we obtained 
from the literature an estimate of the corresponding 
quality of life (QoL), specifically for non-small cell lung 
cancer (NSCLC) and for small cell lung cancer (SCLC). 
Phases and corresponding weights are reported in 
Table 2 for the baseline scenario [31] and for an alterna-
tive scenario based on the results of a meta-analysis [32] 
used for sensitivity analysis (columns 3 and 4).
A correction of QoL for false positive screens related 
to anxiety (QoL index =  0.88 for 3  months) was made, 
according to Earle et al. [33].
After reviewing the literature on LC screening with CT, 
Black et  al. could not draw any conclusions on whether 
the intervention was cost-effective [34]; it had been 
observed that the variety of modelling assumptions made 
in different economic evaluations is the main reason for 
the widely divergent estimates of cost-effectiveness of CT 
screening for LC [35]. In the present study we relied on 
modelling as little as possible, utilizing instead the wealth 
of data gathered from long-term observation of the Invi-
tation-to-screening Group. In particular, to correct for 
potential bias from the varying proportions of censored 
survivors in the different groups, while bearing in mind 
the issue of ambiguity related to modelling assumptions 
that Black et al. [34] highlight, we used information from 
non-censored individuals to correct the value of utility 
assigned to censored observations. In this process we 
assigned to each of these survivors a number of QALYs 
equal to the median of a subset of cases with the long-
est follow-up (those recruited in 1997 and 1998 in the 
PREDICA study), conditional on the length of survival 
at the end of the study and whether the individual was 
screen-detected. The added number of QALYs was the 
excess, if any, between this conditional median and the 
actual number of QALYs through end of follow-up.
A frequent omission in LC screening economic evalu-
ations is the lead-time bias correction [34]. In our study 
we assumed a lead-time bias of 9 months, based on stage 
distribution of screen-detected LCs in the PREDICA 
study [26]; then we subtracted from the utility of screen-
detected LC cases the minimum between 9/12 of QALY 
and the actual number of QALYs. This is a conservative 
assumption because it leads to the attribution of zero 
QALYs to some screen-detected patients even though 
they survive for a number of months. Underlying this 
is another conservative assumption, i.e. that the corre-
sponding months would be spent in perfect health (QoL 
index = 1). Utility values were discounted using a yearly 
discount rate of 3.5 % [36].
Costs
Costs of LC cases were linked to three main activi-
ties: administrative work to run the screening program, 
screening exams, and health care services. Data on 
administrative costs of screening were extracted from the 
balance-sheet of the charity that managed the screening 
program; voluntary work was evaluated using market-
equivalent wages. CXR screening exam costs included 
the cost of follow-up exams to ascertain suspicious or 
Table 2 Phases of lung cancer clinical course and Quality of Life (QoL)
NSCLC non-small cell lung cancer, SCLC small cell lung cancer
a Alternative scenario described in “Methods”; Earle et al. [33]
b Manser et al. [31]
c Sturza [32]
d Where specific information on the QoL index could not be retrieved from the literature, we made the following assumptions: In column 2, for the “postoperative” 
phase we assumed the index for SCLC to be the same as for NSCLC, Line 1 is the same as line 3, In column 2, for the “terminal” phase we assume the index to be the 
same as for the “progression”
Phase of clinical course  
of lung cancer
QoL Index




1. Period of diagnosis 0.88d 0.95d 0.825d 0.605d
2. Chemotherapy 0.82a 0.83a 0.573c 0.353c
3. Postoperative 0.80b 0.80d 0.825c 0.605c
4. Free of disease 0.88a 0.95a 0.825c 0.605c
5. Disease progression 0.69a 0.31a 0.573c 0.353c
6. Terminal phase 0.60b 0.31d 0.573c 0.353c
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false positive CXR screens and the cost of time spent for 
quality assurance and program supervision. For the latter, 
we estimated a workload equivalent to 20 % of a full-time 
consultant physician for the duration of active screen-
ing. Unitary costs for health care treatment and follow-
up were estimated from the corresponding 2012 regional 
tariffs, which are reported in Appendix (Table 5). These 
may differ slightly from National tariffs, although in sev-
eral cases they are the same across Italy.
Because utilities were adjusted to account for censor-
ing, the adjustment was also done for costs. We used 
the same approach as that described above for utilities, 
i.e. we assigned the median cost, conditional on sur-
vival at the end of follow-up and whether the case was 
screen-detected.
All values were expressed in 2012 Euros using the Ital-
ian National Institute of Statistics [37] health care price 
index. The discount rate used for utilities (3.5  %) was 
applied to costs.
Cost‑utility analysis
The cost-effectiveness of a new intervention is usually 
assessed by comparing the Incremental cost-effectiveness 
ratio (ICER) to a threshold value of the maximum Will-
ingness to Pay (WTP) per unit of effectiveness:
where C and E are the difference, respectively, in costs 
and effectiveness of the comparator, and  is the WTP. 
The inequality in the above equation can be equivalently 
expressed in linear form as:
The left side of the equation is the Incremental Net 
Monetary Benefit (INMB). The latter was proposed as 
an alternative to ICER [38] mainly because of the advan-
tages it provides in statistical analysis; it is also widely 
used currently. The INMB measures the incremental net 
benefit of the new intervention in monetary units. In our 
case, the INMB is based on a measure of utility (QALYs) 
and can be calculated as a weighted average across health 
states of individuals:
where, p denotes probability and subscripts refer to the 
following states: lung cancer (LC), false positive ( fp) and 
true negative (tn). INMBLC is calculated using data on 
costs and utilities that are available for both the invita-
tion-to-screening group and the control group. INMBfp 




 ·�E −�C > 0.
INMB = pLC · INMBLC + pfp · INMBfp
+
(
1− pLC − pfp
)
· INMBtn
and it is based again on a conservative assumption, i.e. 
that only screening may lead to a false positive response. 
INMBfp is a negative number that accounts for both addi-
tional costs and anxiety-related QoL implications of a 
false positive screen. Finally, INMBtn is also a negative 
number because of the costs (administration and screen-
ing) assessed even if the individual remains healthy. We 
assume no difference in utility among the groups com-
pared for the true negative.
In addition to the well-known advantages of INMB 
over Incremental Cost-Effectiveness Ratio (ICER) for 
dealing with sampling variance [39], the former approach 
also allows us to study the sensitivity of our results to the 
probability of diagnosed LC and false positive test. This 
is crucial for three reasons: (1) the results tend to be very 
sensitive to these probabilities; (2) the number of LC 
cases that we observed among participants (67) is rela-
tively small, and (3) the statistical error for the estimated 
probability of diagnosed LC may be comparatively large. 
A sensitivity exercise on these probabilities may help 
assess the possibility of extending our results to contexts 
in which LC risk is higher or lower.
We made two estimates of the INMB. First, we com-
pared Screening Participants vs. Control Group, then 
Intervention-to-screening Group vs. Control Group. We 
interpret these results as the cost-utility of screening-par-
ticipation and invitation-to-screening, respectively.
Sensitivity analysis
For baseline analysis, we used the frequency of LC cases 
in Screening Participants and in Intervention-to-screen-
ing Group, after excluding 2 cases of overdiagnosis 
(67/1244 = 0.054 and 243/5815 = 0.042), to estimate pLC. 
Similarly, pfp equals the ratio of the number of individu-
als with a false positive test to the number of participants 
(190/1244  =  0.153). Sensitivity analysis was performed 
by replacing the baseline probability with the extremes of 
the 95 % confidence interval (CI) of the estimated prob-
ability of LC. The other parameters we let vary in the sen-
sitivity analysis were QoL weights (see Table 2) and cost 
levels. For costs, we investigated the impact of an arbi-
trary 20 % increase in all costs, which may inform about 
the possibility of generalizing our results to other health 
care systems. We primarily used two values of the WTP 
that are often referred to in the literature: € 30,000/QALY 
and €50,000/QALY. A general analysis of the impact of 
the WTP was provided by estimating the cost-effective-
ness acceptability curve (CEAC).
Results
Mean values for QALYs and costs of LC cases are shown 
in Table 3. Overall, the mean total cost per LC case was 
higher in Screening Participants (€17,516) than in the 
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control group (€15,503). The individual component of the 
costs related to organization and administration of the 
screening program (€307) was obtained by dividing the 
total cost by the number of participants. This component 
is the same for LC cases (Table 3) and true negative indi-
viduals in Screening Participants. The LC management 
costs were also higher in Screening Participants (€17,149) 
than in the control group (€15,503).
Looking at the comparison between the Invitation-to-
screening Group and the Control Group, the incremen-
tal total cost (€16,167–15,503) was €664. Costs related 
to screening activities were lower for the Invitation-
to-screening Group (€100) than for screening partici-
pants. This is because the Invitation-to-screening group 
includes non-participants for whom screening costs were 
imputed to Screening Participants (see above). Finally, 
LC management cost was higher, on average, in the Invi-
tation-to-screening Group (€16,067) than in the control 
group (€15,503) (Table 3).
The average (discounted) number of QALYs since diag-
nosis was 1.70, 1.49, and 1.07, respectively, for screening 
participants, the invitation-to-screening group, and the 
control group. Accordingly, on average Screening Partici-
pants gained 0.63 QALYs and the Invitation-to-screening 
Group gained 0.42 QALYs, relative to the Control Group. 
The combination of these results with costs and utilities 
of true negative and false positive individuals leads to an 
estimate for the individual level INMB of €368 for screen-
ing participation and €365 for invitation-to-screening, 
with a WTP of €30,000 per QALY (Table 4). With a WTP 
of €50,000 per QALY, the estimated INMB increases, 
respectively, to €959 for screening participation and €692 
for invitation-to-screening. Table 4 also shows the prob-
ability that, taking sampling variance into account, the 
intervention is cost-effective for the two levels of WTP 
considered, under the main and the sensitivity scenarios. 
In particular, it is worth noting that a 20  % increase in 
unitary costs does not significantly change the results.
The CEAC provides a more general picture of the rela-
tionship between the level of WTP and the probability 
that screening is cost-effective. Figures  1 and 2 show 
the CEAC for the baseline and sensitivity scenarios. 
Referring once more to the values of WTP per QALY of 
€30,000 and €50,000, the probability that screening par-
ticipation is cost-effective is, respectively, 0.79 and 0.9 in 
the baseline scenario. The corresponding probabilities for 
invitation-to-screening are 0.95 and 0.97. Table 4 summa-
rizes the results of the sensitivity analysis.
Discussion
Based on long-term observation of the population-based 
PREDICA study of CXR screening in smokers [26], our 
assessment of cost-effectiveness of CXR screening for 
LC indicates an expected INMB (WTP: €30,000 per 
QALY) of €368 for the comparison between Screening 
Participants and Control Group in the baseline analy-
sis. This finding implies a 0.79 probability that screening 
participation is cost-effective. Notably, in addition to 
screening-related costs, participants showed higher LC 
management costs due to more frequent surgical proce-
dures performed as a result of early LC detection. More-
over, compared with the Control Group, the Screening 
Participants had markedly improved 5-year survival 
(30.5 vs. 13.0  %) [26] and longer median follow-up 
(Table 1), which added cost to LC management. Because 
we observed only 67 LC cases among Screening Partici-
pants (n = 1244), despite the large number of individuals 
(n = 5815) invited to screening, the variance around the 
central estimate of the INMB is wide. This confirms that 
the assessment of a screening program cost-effectiveness 
requires substantial investment of resources and pro-
longed observation.
Our study has limitations. First, it is not a randomized 
study and therefore is subject to the selection bias of 
screening volunteers, as previously noted [27]. Second, 
in our study the proportion of censored observations was 
different across groups. We addressed this potential bias 
by adjusting utilities and costs of censored observations 
using the wealth of information available on non-cen-
sored patients.
Table 3 Mean costs and QALYs per lung cancer (LC) case in screening participants, invitation-to-screening group and con-
trol group
All amounts are in Euros 2012. Standard deviation in parenthesis. Values are rounded to the nearest integer
Screening participants Invitation‑to‑screening group Control group
Mean costs per LC case
 Screening organization and administration 307 (0) 84 (0) –
 CXR screening 60 (44) 16 (35) –
 LC management 17,149 (4783) 16,067 (4948) 15,503 (4518)
Mean total cost per LC case 17,516 (4755) 16,167 (4729) 15,503 (4521)
Mean QALYs (baseline scenario) 1.70 (2.1) 1.49 (1.9) 1.07 (1.7)
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A strength of our study is the Control Group consist-
ing of uninvited and unscreened LC patients, with 92 % 
complete follow-up. The Control Group LCs were nearly 
contemporary to those of the Invitation-to-screening 
Group and were gathered from the same geographical 
area. Another strength of the study is that information 
was gathered on LC cases that occurred in individuals 
who were invited to the screening program and decided 
Table 4 Sensitivity analysis testing the probability that screening participation or invitation-to-screening is cost-effective
INMB incremental net monetary benefit, WTP willingness to pay, LC lung cancer
INMB Probability cost‑effective
WTP (€ per QALY) 30,000 WTP (€ per QALY) 50,000 WTP (€ per QALY) 30,000 WTP (€ per QALY) 50,000
Screening participation (group P vs. group C)
 Base-case 368 959 0.79 0.89
 High prob of LC (pLC = 6.79 %) 609 1376 0.86 0.92
 Low prob of LC (pLC = 4.2 %) 160 600 0.67 0.84
 Alternative QoL 134 568 0.63 0.80
 Higher costs 265 856 0.72 0.87
Invitation-to-screening (group I vs. group C)
 Base-case 365 692 0.95 0.97
 High prob of LC (pLC = 4.73 %) 438 816 0.96 0.97
 Low prob of LC (pLC = 3.68 %) 311 601 0.94 0.97
 Alternative QoL 260 519 0.90 0.93
 Higher costs 339 667 0.94 0.96
Fig. 1 Cost-effectiveness acceptability curve for screening participation (screening participants vs. control group) in the baseline and sensitivity sce-
narios (see text, “Sensitivity analysis”)
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not to participate. Thus, we were able to assess the overall 
cost-utility of invitation-to-screening by comparing the 
Invitation-to-screening Group with the Control Group. 
This comparison yielded an expected value of individual 
INMB of €365, indicating that invitation-to-screening is 
cost-effective with a probability of 0.95. The small differ-
ence with the central estimate of INMB obtained from 
the previous comparison (€368 vs. €365) is due to the fact 
that invited subjects who did not participate had LC costs 
similar to the Control Group, but achieved more QALYs.
Clearly, our estimates may be affected by local context 
(costs, incidence of LC, WTP); however, our probabilistic 
sensitivity analysis showed limited impact of changes in 
these variables on results.
The estimated probability that the intervention is cost-
effective is higher for invitation-to-screening than for 
screening participation, despite the very close central 
estimates for the INMB. This finding is related to the var-
iance of the sample mean, which is greater when Screen-
ing Participants (a subset of the invitation-to-screening 
group) are compared with the Control Group (67 LC 
cases vs. 156). Moreover, screening invitation per se, 
regardless of participation, might have an impact on LC 
management. The impact of invitation and its economic 
implications are potentially of great interest and worth 
exploring further in different contexts. There may also 
be relevant policy implications. Because the number of 
invited individuals typically exceeds the number of par-
ticipants in screening programs, the total net benefit of 
the program (individual INMB times the population size) 
should also take into account any impact on the invited 
population, in addition to the effect on participants.
Results from the PREDICA study suggest that the total 
net benefits of a LC screening program may be greater 
than expected based on the analysis of screened indi-
viduals only. Implementation of the PREDICA annual 
CXR screening program at population level in smokers 
of the Varese area was associated with an 18 % reduction 
of LC-specific mortality [9]. Because our study shows 
that CXR screening of high-risk smokers can be “good 
value for the money”, the findings may help decision-
makers allocate more efficiently the available health care 
resources. The NLST trial showed that screening for LC 
with CT reduced LC mortality by 20  % compared with 
CXR screening [11]. Based on this finding, leading cancer 
organizations currently recommend LC screening with 
LC low-dose CT [12, 40]. However, low-dose CT screen-
ing is an expensive technique not readily available in 
Fig. 2 Cost-effectiveness acceptability curve for invitation-to-screening (invitation-to-screening group vs. control group) in the baseline and sensitivity 
scenarios (see text, “Sensitivity analysis”)
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many parts of the world. Moreover, low-dose CT screen-
ing is associated with a relevant rate of overdiagnosis and 
of false positive findings [11, 41]. It has been emphasized 
that if early detection of LC provides a benefit, it does 
so regardless of whether the detection is made by CT or 
CXR screening; however, the feasibility of the detection 
method applied to a large number of subjects as a public 
health measure is essential [42]. Chest radiography is a 
simple exam with modest radiation exposure. It is widely 
available, relatively inexpensive, and non-invasive. Addi-
tionally, CXR screening causes negligible overdiagnosis 
of LC [21] and a low rate of false-positive results [22, 26].
In conclusion, based on the PREDICA study [9, 26], 
annual CXR screening of high-risk smokers in the gen-
eral practice setting is a feasible and affordable interven-
tion that has high probability of being cost-effective. This 
finding may have important policy implications in terms 
of resource allocation in health care systems. However, 
before recommending annual screening of heavy smok-
ers by CXR, the results obtained in the present study 
need to be validated by other similar studies in different 
geographical areas and different health systems.
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Table 5 Cost of health care services for diagnosis, staging, treatment and follow-up of lung cancer
Cost components Unitary cost (EURO 2012) Source
Cyto-/histologic confirmation of NSCLC/SCLC
 Bronchoscopy with biopsy 184.74 Tariff 2012 BRL
 Cytology of sputum/pleural fluid 27.45 Tariff 2012 BRL
 CT-guided fine needle aspirate and cytology 160.99 Tariff 2012 BRL
 Day hospital stay 624.00 Tariff 2012 BRL
Total 997.18
Evaluation of stage I–IV LC
 Blood cells count, chemistry, markers, gases 117.25 Tariff 2012 BRL
 EKG 11.60 Tariff 2012 BRL
 CXR exam, dual projection 17.40 Tariff 2012 BRL
 Chest CT without and with contrast 164.67 Tariff 2012 BRL
 Abdomen CT without and with contrast 168.37 Tariff 2012 BRL
 Head CT without and with contrast 159.93 Tariff 2012 BRL
 Bone scintigraphy 111.90 Tariff 2012 BRL
 Spirometry 23.75 Tariff 2012 BRL
 Hospital stay (average 7 days) 4160.00 Tariff 2012 BRL
Total 4934.87
Evaluation of indeterminate stage LC
 Blood cells count, chemistry, markers, gases 117.25 Tariff 2012 BRL
 EKG 11.60 Tariff 2012 BRL
 CXR exam, dual projection 17.40 Tariff 2012 BRL
 Chest CT without and with contrast 164.67 Tariff 2012 BRL
 Abdomen CT without and with contrast 168.37 Tariff 2012 BRL
 Head CT without and with contrast 159.93 Tariff 2012 BRL
 Hospital stay (average 4 days) 2496.00 Tariff 2012 BRL
Total 3135.22
 Operating room occupancy (average 180 min.) 3000.00 Varese Hospital Admin.
 Operating room materials 1500.00 Varese Hospital Admin.
 Hospital stay in surgical unit (average 12 days) 6600.00 Varese Hospital Admin.
 Total 11,100.00
Chemotherapy for LC stage III
 6 Cycles (Cisplatin + Gemcitabine) 8989.62 Oncology Unit Varese Hospital
Chemotherapy for LC stage IV
 3 Cycles (Cisplatin + Gemcitabine) 4494.81 Oncology Unit Varese Hospital
Palliative radiotherapy 4934.55 Radiotherapy Unit Varese Hosp.
Radical radiotherapy (50–60 Gy) 7849.46 Radiotherapy Unit Varese Hosp
Chemo-Radiotherapy combined 10,091.03 Onc./Radiot.Units Varese Hosp.
Supportive/palliative therapy 2759.76 Tariff 2012 BRL
Terminal phase care (1 month) 1800.00 Tariff 2012 BRL
Follow-up: first year
 3 Physical exams 74.10 Tariff 2012 BRL
 2 CXR exams, dual projection 34.80 Tariff 2012 BRL
 2 Blood cells counts, chemistry, markers, gases 234.50 Tariff 2012 BRL
 1 Chest CT exam without and with contrast 164.67 Tariff 2012 BRL
 Total 508.07
Follow-up: second year
 2 Physical exams 49.40 Tariff 2012 BRL
 1 CXR exam, dual projection 17.40 Tariff 2012 BRL
 2 Blood cells counts, chemistry, markers, gases 234.50 Tariff 2012 BRL
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